Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1988:35 Suppl 2:29-34.
doi: 10.2165/00003495-198800352-00008.

Cefotaxime combined with selective decontamination in long term intensive care unit patients. Virtual absence of emergence of resistance

Affiliations

Cefotaxime combined with selective decontamination in long term intensive care unit patients. Virtual absence of emergence of resistance

H K van Saene et al. Drugs. 1988.

Abstract

Emergence of bacterial resistance to antimicrobial agents was studied during a period of 30 months of continuous use of parenteral cefotaxime combined with oral non-absorbable polymyxin E and tobramycin (selective decontamination) in a surgical intensive care unit (ICU). No increase in drug-resistance micro-organisms was found. Colonisation of the oropharyngeal cavity or intestine or both by strains resistant to polymyxin E occurred in 8% of patients (invariably Proteus and Morganella species). Tobramycin-resistant strains (Escherichia coli, Acinetobacter and Pseudomonas species) were found in 4% of patients. Intestinal colonisation with cefotaxime-resistant bacilli (e.g. Enterobacter, Pseudomonas and Acinetobacter species) occurred in 10% of patients, but in most patients these strains were eliminated by therapy with the topical antibiotics within one week. The control of emergence of resistance has major implications for the antibiotic policy in the ICU: firstly, the number of different antimicrobials used is sharply reduced since the switching of antibiotics to treat suprainfections is seldom necessary; secondly, it is possible to use a third generation cephalosporin such as cefotaxime for systemic prophylaxis, without risk of induction of resistance.

PubMed Disclaimer

Similar articles

Cited by

References

    1. J Infect Dis. 1983 Mar;147(3):585-9 - PubMed
    1. Pathol Biol (Paris). 1974 Jan;22(1):5-12 - PubMed
    1. Am J Med. 1981 Feb;70(2):449-54 - PubMed
    1. J Hyg (Lond). 1980 Aug;85(1):141-51 - PubMed
    1. Crit Care Med. 1987 Feb;15(2):99-102 - PubMed

LinkOut - more resources